Effect of Probiotic Consumption in individuals with Heart Diseases

Not Applicable

• Conditions: Multiple valve diseases; I49.9; I50.0; I20-I25; Hypertensive heart disease; Congestive heart failure; Cardiac arrhythmia, unspecified; Ischaemic heart diseases; Myocardial Infarction

• Registration Number: RBR-6ztyb7
• Lead Sponsor: niversidade Federal da Grande Dourados - UFGD

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-02-20
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Adult and elderly volunteers; both sexes; undergoing clinical or surgical treatment for cardiovascular disease.

Exclusion Criteria

Previous gastrointestinal diseases; Chronic kidney disease on dialysis; Food intolerances or food allergies; Alcohol or illicit drug addiction; Current or previous use (up to three months) of antibiotics, laxatives and appetite suppressants; Regular use of antispasmodics or antacids; Current or previous use (up to three months) of dietary fiber modules, prebiotics, probiotics, synbiotics or products enriched with these ingredients; Present intolerance to prebiotics, probiotics, synbiotics; Pregnant or lactating women; Current follow-up of unusual diets (vegetarian, paleolithic, gluten-free, lactose-free, macrobiotic); Indigenous people.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction in C-reactive protein concentrations, verified by laboratory determination of this marker in blood plasma before (baseline) and after 30 and 90 days of supplementation (final). The average C-reactive protein concentrations in the intervention group will be compared with the control group.